{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:50:15Z","timestamp":1761663015984},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.mehy.2011.10.030","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T15:30:52Z","timestamp":1321543852000},"page":"225-226","source":"Crossref","is-referenced-by-count":3,"title":["Potential role of TNF alpha blockers in delaying the progression of hepato-renal syndrome"],"prefix":"10.1016","volume":"78","author":[{"given":"Faryal","family":"Tahir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haris","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anis","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Bilal","family":"Munir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2011.10.030_b0005","first-page":"11","article-title":"Lam. Hepatorenal syndrome","volume":"28","author":"Ng","year":"2007","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.mehy.2011.10.030_b0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mehy.2011.10.030_b0015","first-page":"583","article-title":"Tumor necrosis factor-alpha enhances the effect of endothelin on renal vasoconstriction in isolated perfused rat kidney","volume":"11","author":"Wen","year":"2003","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.mehy.2011.10.030_b0020","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mehy.2011.10.030_b0025","first-page":"96A","article-title":"Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis","volume":"14","author":"McHutchison","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.mehy.2011.10.030_b0030","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3748\/wjg.15.1613","article-title":"Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial","volume":"15","author":"De","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mehy.2011.10.030_b0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MEG.0b013e3283435d76","article-title":"Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo","volume":"23","author":"Tyagi","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.mehy.2011.10.030_b0040","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3748\/wjg.15.3194","article-title":"Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?","volume":"15","author":"Assimakopoulos","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mehy.2011.10.030_b0045","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/j.1572-0241.1998.00587.x","article-title":"Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology","volume":"93","author":"McCullough","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mehy.2011.10.030_b0050","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1111\/j.1440-1746.2007.05286.x","article-title":"Treatment of severe forms of alcoholic hepatitis: where are we going?","volume":"23","author":"Mathurin","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.mehy.2011.10.030_b0055","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987711005573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987711005573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T11:56:32Z","timestamp":1543406192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987711005573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0306987711005573"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2011.10.030","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}